<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01628068</url>
  </required_header>
  <id_info>
    <org_study_id>ELIGIBLE</org_study_id>
    <secondary_id>Estudio ELIGIBLE</secondary_id>
    <nct_id>NCT01628068</nct_id>
  </id_info>
  <brief_title>ELIGIBLE (Efficacy of Left atrIal Appendage Closure After GastroIntestinal BLEeding)</brief_title>
  <acronym>ELIGIBLE</acronym>
  <official_title>Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with atrial fibrillation requiring anticoagulation treatment are at high risk of
      gastrointestinal bleeding. The investigators propose the percutaneous stop the oral
      anticoagulation and closure of the left atrial appendage with the Amplatzer ® system in
      patients receiving anticoagulant therapy for atrial fibrillation without associated valvular
      heart disease, to reduce significantly the risk of stroke while minimizing the risk of
      bleeding in a group of patients with high risk for both events.

      ELIGIBLE trial(Left atrial appendage Efficacy of GastroIntestinal Bleeding after closure) is
      a prospective, multicentric and randomized (2 to 1) trial, comparing percutaneous closure of
      atrial appendage left versus standard treatment with oral anticoagulants in patients with
      history of gastrointestinal bleeding and high embolic risk.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined overall mortality, major bleeding, stroke or procedure-related complications</measure>
    <time_frame>1 year</time_frame>
    <description>The primary end point will be at one year the combined overall mortality, major bleeding, stroke or procedure-related complications.
Mortality from any cause
Severe bleeding defined according to VARC criteria
Ischemic stroke or hemorrhagic stroke at 12 months.
Complications related to the procedure: include:
device embolization
severe pericardial effusion with hemodynamic compromise that requires drainage
Device thrombosis
cardiac perforation
major local complications (according to definitions of VARC)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Adverse Reaction to Drugs Affecting the Gastrointestinal System</condition>
  <arm_group>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral anticoagulation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Oral anticoagulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Left atrial appendage occlusion</intervention_name>
    <description>Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months</description>
    <arm_group_label>Left atrial appendage occlusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented atrial fibrilation (paroxysmal or permanent) without significant heart
             valve disease

          -  &gt; 18 years

          -  Classic oral anticoagulation(INR at therapeutic levels: 2-3) or New oral
             anticoagulants

          -  CHA2-DS2-VASC score ≥ 3

          -  prior digestive bleeding without any treatable cause

          -  Informed consent.

        Exclusion Criteria:

          -  POF

          -  contraindication to further treatment with dual antiplatelet therapy (aspirin +
             clopidogrel)

          -  Intracardiac thrombus

          -  significant carotid disease

          -  Cardioversion scheduled within 30 days following the implantation

          -  AF not controlled by FVM&gt; 100 bpm

          -  AF secondary to surgery or ablation

          -  thrombosis in patients &lt;40 years

          -  chronic renal insufficiency with Cr clearance &lt;30 ml 2

          -  left appendage sizeappendage with inlet &lt;12.6 mm or &gt; 28.5 (ETE)

          -  depth of the appendage &lt;10mm in the TEE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victoria Martín Yuste, MD, PhD</last_name>
    <phone>+34-93-227-55-19</phone>
    <email>vmartiny@clinic.ub.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <state>Mdrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Goicolea, MD</last_name>
    </contact>
    <investigator>
      <last_name>Javier Goicolea, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Antonio Fernández Díaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina</name>
      <address>
        <city>Badajoz</city>
        <zip>06006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Ramón López Mínguez, MD, PhD</last_name>
      <phone>+34-924218100</phone>
      <email>lópez-mínguez@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>José Ramón López Mínguez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundació Clínic per a la Recerca Biomèdica</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Martín Yuste, MD, PhD</last_name>
      <phone>+34-932275400</phone>
      <email>vmartiny@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Victoria Martín Yuste, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manel Sabaté Tenas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raúl Moreno, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Raúl Moreno, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José María Hernández García, MD</last_name>
    </contact>
    <investigator>
      <last_name>José María Hernández García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Ruiz Salmerón, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rafael Ruiz Salmerón, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>June 25, 2012</last_update_submitted>
  <last_update_submitted_qc>June 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Victoria Martin Yuste</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Left atrial appendage occlusion</keyword>
  <keyword>gastrointestinal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

